Xcell Therapeutics (Biotechnology) is Biotechnology in South Korea that focus on developer business. Founded in 2015. They cover business area such as developer, cell therapy development, production, great consistency, a control environment, ingredient, researcher, clinician, human mesenchymal stem cell.
2015
( 9 years old in 2024 )
Developer
-
333, Yeongdong-daero
Dongwon Building, 6th Floor
Seoul, Gangnam-gu 06188
South Korea
Private
developercell therapy developmentproductiongreat consistencya control environmentingredientresearcherclinicianhuman mesenchymal stem cell
* We use standard office opening hours in near Xcell Therapeutics (Biotechnology)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Xcell Therapeutics (Biotechnology) is Biotechnology business from South Korea that founded in 2015 (9 years old in 2024), Xcell Therapeutics (Biotechnology) business is focusing on Developer.
Xcell Therapeutics (Biotechnology) headquarter office and corporate office address is located in 333, Yeongdong-daero Dongwon Building, 6th Floor Seoul, Gangnam-gu 06188 South Korea.
Xcell Therapeutics (Biotechnology) was founded in South Korea.
In 2024, Xcell Therapeutics (Biotechnology) is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Xcell Therapeutics (Biotechnology), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
